Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy

被引：26
|
作者：
Bahrami, Afsane [1 ,2 ]
Amerizadeh, Forouzan [1 ,2 ]
Hassanian, Seyed Mahdi [3 ,4 ]
ShahidSales, Soodabeh [5 ]
Khazaei, Majid [6 ]
Maftouh, Mina [3 ]
Ghayour-Mobarhan, Majid [3 ]
Ferns, Gordon A. [7 ]
Avan, Amir [3 ]
机构：
[1] Mashhad Univ Med Sci, Fac Med, Dept Modern Sci & Technol, Mashhad, Iran
[2] Mashhad Univ Med Sci, Fac Med, Student Res Comm, Mashhad, Iran
[3] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Iran
[4] Mashhad Univ Med Sci, Dept Med Biochem, Fac Med, Mashhad, Iran
[5] Mashhad Univ Med Sci, Canc Res Ctr, Mashhad, Iran
[6] Mashhad Univ Med Sci, Fac Med, Dept Physiol, Mashhad, Iran
[7] Brighton & Sussex Med Sch, Div Med Educ, Brighton, Sussex, England
来源：
JOURNAL OF CELLULAR PHYSIOLOGY | 2018年 / 233卷 / 03期
关键词：
colorectal cancer; oxaliplatin; predictive biomarkers; resistance; DNA-REPAIR GENES; GLUTATHIONE-S-TRANSFERASE; GROWTH-FACTOR-RECEPTOR; MICROSATELLITE INSTABILITY; ADJUVANT CHEMOTHERAPY; CHROMOSOMAL INSTABILITY; THERAPEUTIC PROGNOSIS; FOLFOX-4; CHEMOTHERAPY; CISPLATIN RESISTANCE; CHINESE POPULATION;
D O I：
10.1002/jcp.25966
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Chemotherapy regimen containing oxaliplatin is often the first-line treatment for patient with advanced colorectal cancer. Oxaliplatin binds to DNA, leading to the formation of crosslinks and bulky adducts. Approximately 50% of patients with CRC benefit from treatment with oxaliplatin. It is possible that genetic variants in biological pathways involved in drug transportation, drug metabolism, DNA damage repair, and cell cycle modulation might affect the activity, or efficacy of oxaliplatin. Because oxaliplatin resistance may be related to these genetic variants and may therefore be an important reason for treatment failure, we have summarized the genetic variations that have been reported to be predictive markers of the response to oxaliplatin based therapy in patients with advanced CRC.
引用
收藏
页码：2193 / 2201
页数：9
相关论文
共 50 条
  • [1] Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy
    Park, Hanla A.
    Seibold, Petra
    Edelmann, Dominic
    Benner, Axel
    Canzian, Federico
    Alwers, Elizabeth
    Jansen, Lina
    Schneider, Martin
    Hoffmeister, Michael
    Brenner, Hermann
    Chang-Claude, Jenny
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2022, 31 (02) : 352 - 361
  • [2] Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy
    de Gramont Lesparre, A. H.
    Chibaudel, B.
    Bourges, O.
    Perez-Staub, N.
    Tournigand, C.
    Maindrault-Goebel, F.
    Andre, T.
    Larsen, A. K.
    Afchain, P.
    Louvet, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] DEFINITION OF OXALIPLATIN SENSITIVITY IN PATIENTS WITH ADVANCED COLORECTAL CANCER PREVIOUSLY TREATED WITH OXALIPLATIN-BASED THERAPY
    de Gramont, A.
    Chibaudel, B.
    Bourges, O.
    Perez-Staub, N.
    Tournigand, C.
    Maindrault-Goebel, F.
    Andre, T.
    Larsen, A.
    Afchain, P.
    Louvet, C.
    ANNALS OF ONCOLOGY, 2009, 20 : 13 - 13
  • [4] Genetic variants in RPA1 associated with the response to oxaliplatin-based chemotherapy in colorectal cancer
    Shuwei Li
    Kaili Xu
    Dongying Gu
    Lei He
    Lisheng Xie
    Zhengxin Chen
    Zhimin Fan
    Lingjun Zhu
    Mulong Du
    Haiyan Chu
    Zhengdong Zhang
    Yuan Wu
    Min Ni
    Meilin Wang
    Journal of Gastroenterology, 2019, 54 : 939 - 949
  • [5] Genetic variants in RPA1 associated with the response to oxaliplatin-based chemotherapy in colorectal cancer
    Li, Shuwei
    Xu, Kaili
    Gu, Dongying
    He, Lei
    Xie, Lisheng
    Chen, Zhengxin
    Fan, Zhimin
    Zhu, Lingjun
    Du, Mulong
    Chu, Haiyan
    Zhang, Zhengdong
    Wu, Yuan
    Ni, Min
    Wang, Meilin
    JOURNAL OF GASTROENTEROLOGY, 2019, 54 (11) : 939 - 949
  • [6] Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy
    L Paré-Brunet
    A Sebio
    J Salazar
    A Berenguer-Llergo
    E Río
    A Barnadas
    M Baiget
    D Páez
    The Pharmacogenomics Journal, 2015, 15 : 397 - 404
  • [7] Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy
    Pare-Brunet, L.
    Sebio, A.
    Salazar, J.
    Berenguer-Llergo, A.
    Rio, E.
    Barnadas, A.
    Baiget, M.
    Paez, D.
    PHARMACOGENOMICS JOURNAL, 2015, 15 (05): : 397 - 404
  • [8] Oxaliplatin-based chemotherapy in the management of colorectal cancer
    Capdevila, Jaume
    Elez, Elena
    Peralta, Sergio
    Macarulla, Teresa
    Javier Ramos, Francisco
    Tabernero, Josep
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (08) : 1223 - 1236
  • [9] Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer
    E J Kap
    P Seibold
    S Richter
    D Scherer
    N Habermann
    Y Balavarca
    L Jansen
    N Becker
    K Pfütze
    O Popanda
    M Hoffmeister
    A Ulrich
    A Benner
    C M Ulrich
    B Burwinkel
    H Brenner
    J Chang-Claude
    The Pharmacogenomics Journal, 2015, 15 : 505 - 512
  • [10] Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer
    Kap, E. J.
    Seibold, P.
    Richter, S.
    Scherer, D.
    Habermann, N.
    Balavarca, Y.
    Jansen, L.
    Becker, N.
    Pfuetze, K.
    Popanda, O.
    Hoffmeister, M.
    Ulrich, A.
    Benner, A.
    Ulrich, C. M.
    Burwinkel, B.
    Brenner, H.
    Chang-Claude, J.
    PHARMACOGENOMICS JOURNAL, 2015, 15 (06): : 505 - 512
12345